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BACKGROUND: We conducted a multicentre Phase 1b/2 trial to evaluate the safety and efficacy of mapatumumab, a fully human
agonistic monoclonal antibody to the tumour necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) in patients with
relapsed non-Hodgkin’s lymphoma (NHL).
METHODS: Forty patients with relapsed or refractory NHL were treated with either 3 or 10mgkg
 1 mapatumumab every 21 days. In
the absence of disease progression or prohibitive toxicity, patients received a maximum of six doses.
RESULTS: Mapatumumab was well tolerated, with no patients experiencing drug-related hepatic or other dose-limiting toxicity. Three
patients with follicular lymphoma (FL) experienced clinical responses, including two with a complete response and one with a partial
response. Immunohistochemistry staining of the TRAIL-R1 suggested that strong staining in tumour specimens did not appear to be a
requirement for mapatumumab activity in FL.
CONCLUSIONS: Mapatumumab is safe and has promising clinical activity in patients with FL.
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Mapatumumab (HGS-ETR1, TRM-1) is a fully human IgG1
monoclonal antibody specific and agonistic to the tumour necrosis
factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1,
DR4). The TRAIL-R1 is expressed more frequently on the surface
of tumour cells than on the surface of normal cells (Zang et al,
2001; Koornstra et al, 2003). Mapatumumab, like the native ligand
TRAIL, mediates apoptosis by binding to TRAIL-R1, leading to
activation of the caspase cascade, cleavage of key intracellular
signalling components and DNA and subsequent cell death (Pukac
et al, 2005). Mapatumumab induces apoptosis in a wide range of
haematologic and solid tumour cell lines and xenograft models
(Snell et al, 1997; Georgakis et al, 2005; Pukac et al, 2005; Menoret
et al, 2006). In addition to a direct induction of apoptosis,
mapatumumab may also induce antibody-dependent cellular
cytotoxicity. Furthermore, in vivo experiments using disseminated
B cell lymphoma models showed that mapatumumab in combination
with rituximab increased animal survival compared with control,
rituximab alone or mapatumumab alone (Maddipatla et al, 2007).
Mapatumumab was evaluated first as a single agent and
subsequently in combination with chemotherapeutic agents in a
series of Phases 1, 1b and 2 clinical trials (Tolcher et al, 2007;
Greco et al, 2008; Hotte et al, 2008; Mom et al, 2009; Trarbach et al,
2010). In general, it is well tolerated both as a single agent and
in combination with chemotherapy. No disease response
was observed in the other single-agent trials. This clinical trial
was designed to evaluate single-agent mapatumumab in non-
Hodgkin’s lymphoma (NHL). The doses and design were based on
data available from the initial and on-going Phase 1 trials of
mapatumumab (Tolcher et al, 2007; Hotte et al, 2008).
MATERIALS AND METHODS
Patients
Eligibility criteria included histologically confirmed NHL with
measurable disease X1.5cm in the longest transverse diameter by
computed tomography scan. Patients were previously treated with
at least one therapeutic regimen and had relapsed or progressed,
or failed to achieve an objective response after their last
therapeutic regimen. Adequate haematologic, bone marrow,
hepatic and renal functions, and an Eastern Cooperative Oncology
Group performance status 0–2 were required. Patients were
excluded if they had been treated with a monoclonal antibody or
radioimmunotherapy within 8 weeks or had persistent clinical
evidence of toxicity, were eligible for stem cell transplantation
(SCT), had undergone autologous SCT within 16 weeks or had ever
undergone allogeneic SCT. The IRB-approved, written informed
consent was obtained from all patients.
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This multicentre, open-label study was designed to evaluate the
safety and efficacy of mapatumumab in patients with relapsed or
refractory NHL. At the time this study was initiated, safety data
were available from on-going Phase 1 trials for doses up to
3mgkg
 1 every 28 days. This trial was designed to allow for
treatment of a small number of NHL patients with 3mgkg
 1 every
21 days before treating a larger number of patients with 10mgkg
 1
every 21 days. Specifically, safety data from eight patients treated
with 3mgkg
 1 mapatumumab were reviewed before enrolment
of the 10mgkg
 1 cohort. Mapatumumab was administered intra-
venously (i.v.) over 2h in a total volume of 250ml normal saline.
No dose reduction was allowed. Premedication with diphenhydr-
amine and acetaminophen was allowed and usually given. Patients
were treated on day 1 of each 21(±2)-day cycle for up to six
cycles in the absence of disease progression or dose-limiting
toxicity. Patients who demonstrated a tumour response after six
cycles of treatment could receive permission to continue
treatment. Disease assessment was performed at baseline, and
after cycles three and six, and then every 3-month intervals until
disease progression. Disease response was evaluated using
response criteria according to the International Working Group
Recommendations for NHL (Cheson et al, 1999). Adverse events
(AEs) and clinical laboratory test results were graded based on the
NCI-CTCAE (Version 3.0).
Plasma mapatumumab concentrations were measured before
dosing, immediately post-dosing and 4–6h post-dosing for the
first mapatumumab administration. Additional sampling was
performed before dosing, immediately post-dosing and 24h
post-dosing after the second administration, and before dosing
and day 17 (day of disease assessment) for the third and sixth
administration. Anti-mapatumumab antibodies were analysed
using an enzyme-linked immunosorbent assay. Serum samples
were obtained at baseline, prior to dosing in each treatment cycle,
at cycle 1, day 17 and 28–30 days after the last dose of
mapatumumab. Formalin-fixed, paraffin-embedded tissue blocks
or 4–6mm tissue sections from biopsies collected at baseline,
post-dose or from archival specimens were requested from all
patients and collected as available. The immunohistochemistry
(IHC) staining method utilised standardised reagents according
to a protocol supplied by DAKO (Carpinteria, CA, USA) for
this prototype pharmDx test intended for investigative use
(Humphreys and Halpern, 2008).
Statistical considerations
Progression-free survival was calculated from baseline to disease
progression (or death) using the Kaplan–Meier method. To assess
potential relationships between AEs and plasma mapatumumab
concentrations, dose normalised plasma mapatumumab concen-
trations at selected time points were compared among patients
who experienced serious adverse event (SAEs) and those who
did not, only if nX3 for each subgroup, using two-sided unpaired
t-tests at a significance level of a¼0.05.
RESULTS
Among the 40 patients treated in this study, 8 received 3mgkg
 1
mapatumumab and 32 received 10mgkg
 1 mapatumumab. Patient
demographics and baseline disease characteristics are summarised
in Table 1. The majority of patients (26 out of 40, 68%) completed
at least 3 cycles and 12 patients received the full 6 cycles. Two
patients receiving 10mgkg
 1 demonstrated a tumour response
after six cycles and received permission to continue mapatumu-
mab until disease progression. One patient received 12 cycles,
discontinued the study for an unrelated medical condition and, at
the time of discontinuation, had an increase in tumour size not yet
reaching disease progression. The other patient received 27 cycles
before disease progression. Three patients with follicular lympho-
ma (FL) (Grade 1 or 2) achieved major responses: one complete
response (CR) in the 3mgkg
 1 cohort, and one partial response
(PR) and one CR in the 10mgkg
 1 cohort. The median time
to response (CR or PR) was 3.9 months (range: 1.8–4.1 months).
The patient in the 3-mgkg
 1 cohort achieved a PR after
completing six cycles of treatment; her tumour continued to
shrink, and she achieved a CR at 11.4 months. The mechanism of
this continued response is unknown, but based on the plasma half-
life of mapatumumab, the subject would have been exposed to
mapatumumab for several months after discontinuing drug. This
patient had disease progression at 26 months. The two patients
in the 10mgkg
 1 cohort who achieved disease response after six
cycles received IRB permission to continue on mapatumumab.
The patient with the PR received a total of 12 cycles and was taken
off study to allow for treatment of bilateral urethral stones. This
patient had progressing disease at the time of discontinuation at
8.5 months with a 45.9% increase in tumour. The second patient
received 27 cycles and converted from a PR to a CR at 9.3 months.
The patient exhibited progressive disease after 21 months. A total
of six patients experienced tumour shrinkage following mapatu-
mumab therapy (Figure 1A). The median PFS for all patients in
the study was 2 months (Figure 1B). For the subset of 17 FL
patients, the median PFS was 6 months (95% CI: 2.1–21 months).
Table 1 Patient demographic and baseline disease characteristics
3mgkg
–1
(n¼8)
10mgkg
–1
(n¼32)
Total
(n¼40)
Sex
Male 4 (50%) 20 (63%) 24 (60%)
Female 4 (50%) 12 (38%) 16 (40%)
Race
White 7 (88%) 31 (97%) 38 (95%)
Black or African American 1 (13%) 1 (3%) 2 (5%)
Age (years)
Median (range) 63 (51–74) 57 (32–81) 60 (32–81)
Time from first diagnosis (months)
Median (range) 36 (5–88) 40.5 (9–322) 40 (5–322)
Number of prior systemic regimens
Median (range) 3.5 (1–12) 3.0 (1–9) 3.0 (1–12)
Rituximab – combination or single
agent (B-cell lymphoma patients)
8/8 (100%) 26/28 (93%) 34/36 (94%)
ECOG performance status
0 3 (38%) 19 (60%) 22 (55%)
1 5 (63%) 11 (34%) 16 (40%)
2 2 (6%) 2 (5%)
Histological classification at diagnosis
Small lymphocytic 1 (3%) 1 (3%)
Marginal zone 1 (3%) 1 (3%)
Follicular 2 (25%) 15 (47%) 17 (43%)
Grade 1 7 (22%) 7 (18%)
Grade 2 2 (25%) 6 (19%) 8 (20%)
Grade 3 1 (3%) 1 (3%)
Unclassified 1 (3%) 1 (3%)
Mantle cell 3 (38%) 3 (9%) 6 (15%)
Diffuse large B cell 2 (25%) 7 (22%) 9 (23%)
Anaplastic large cell 1 (3%) 1 (3%)
Peripheral T cell 3 (9%) 3 (8%)
B cell unclassified 1 (13%) 1 (3%) 2 (5%)
Abbreviation: ECOG¼Eastern Cooperative Oncology Group.
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cycles with a PFS of 24 and 21 months, respectively.
The most commonly reported AEs, regardless of relationship to
study drug, are shown in Table 2. Most of these events were Grade
1 or 2 in severity. The most common AEs considered at least
possibly related to mapatumumab included nausea, fatigue,
diarrhoea, anorexia and pyrexia. These events were Grade 1 or 2
with the exception of a single event of Grade 3 pyrexia. Eleven
patients experienced 29 SAEs. Three SAEs reported in the
10mgkg
 1 cohort were considered either possibly, probably or
definitely related to treatment with mapatumumab. One patient
experienced peripheral, facial and angioneurotic oedema, and
discontinued treatment. The other two SAEs, pyrexia and herpes
zoster occurred in a single patient each. Laboratory data showed no
evidence of significant hepatotoxicity or renal toxicity. One patient
developed Grade 3 GGT levels. One developed Grade 2 hyperbilir-
ubinemia. Two patients developed hyperamylasemia (Grade 3 or 4).
No patient developed anti-mapatumumab antibodies.
The mean serum mapatumumab concentration–time profiles
are illustrated in Figure 2. The observed plasma mapatumumab
concentrations tended to be higher than those predicted from the
Phase 1 trials of mapatumumab in solid tumours and is due to a
slower clearance of mapatumumab in these study patients (Tolcher
et al, 2007; Hotte et al, 2008). The terminal elimination half-life
(t1/2,z) was B26 days in NHL patients compared with 12–24
days seen in patients with solid tumours (Tolcher et al, 2007; Hotte
et al, 2008).
Twenty-four patients provided a total of 29 evaluable tissue
specimens: 18 archival specimens, 7 specimens before treatment
and 4 post-treatment. Of these, TRAIL-R1 was detected in 16
specimens from 14 patients, with at least 10% of tumour cells
staining. Tumours with an aggressive phenotype demonstrated the
strongest TRAIL-R1 staining. The TRAIL-R1-specific staining was
not detected or was weak in the archival or baseline specimens
from two of the three patients with FL who responded to
mapatumumab; biopsy material from the third patient was not
evaluable.
DISCUSSION
This is the first trial to demonstrate disease response from single-
agent mapatumumab in lymphoma. The results introduce three
important questions: (1) what dose(s) of mapatumumab should be
evaluated in future studies of mapatumumab in NHL; (2) whether
staining for TRAIL-R1 by IHC can help identify patients most
likely to benefit from mapatumumab and (3) whether mapatumu-
mab should be further evaluated as a single agent for NHL or in
combination with other therapeutics that target relapsed or
refractory NHL.
At the time this study was initiated, safety data were available
from on-going Phase 1 trials in advanced solid tumour patients for
doses up to 3mgkg
 1 every 28 days. Preclinical models showed
mapatumumab to be active in doses that correspond to 3 and
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Figure 1 (A) Best per cent change from baseline in sum of products of diameters (SPD). Nine patients lacking a complete post-baseline disease
assessment are excluded from the figure. (B) Progression-free survival, all patients (n¼40).
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 1. Based on the availability of data from Phase 1 solid
tumour trials and the preclinical models, this trial was designed
to allow for treatment of a small number of NHL patients with
3mgkg
 1 before treating a larger number of patients with
10mgkg
 1. In subsequent clinical trials, doses as high
as 30mgkg
 1 have been administered to solid tumour patients
in combination with chemotherapy. Whether higher doses of
mapatumumab would have led to more patients achieving a CR or
PR is unknown, but safety data from other trials support further
evaluation of higher doses. As TRAIL-R1 is expressed more widely
on the surface of tumour cells than normal cells, staining by IHC
for TRAIL-R1 in tissue specimens of the lymphoma was of special
interest. It is noteworthy that for two patients who experienced a
PR or CR, TRAIL-R1 staining was not detected or was weak. Thus,
strong staining in tumour specimens does not appear to be a
prerequisite for mapatumumab in FL.
Although three patients with FL experienced a CR or PR in
response to single-agent mapatumumab, the first demonstration of
disease response from single-agent mapatumumab in lymphoma,
the biology of the TRAIL receptors, preclinical studies of
mapatumumab and accruing clinical data emphasise that mapa-
tumumab is likely to be most efficacious when administered in
combination with other agents, notably agents that affect the
downstream ‘checks and balances’ of the apoptosis pathways
(Jin et al, 2007; Maddipatla et al, 2007; Smith et al, 2007). It is
noteworthy that dulanermin, Apo2L/TRAIL, which activates the
extrinsic pathway through both TRAIL-R1 and TRAIL-R2, did not
improve overall response when combined with rituximab in
patients with relapsed FL (Belada et al, 2010). Accordingly, on-
going randomised Phase 2 trials of mapatumumab in combination
with bortezomib and sorafenib will be highly informative with
regard to the selection of agents to combine with mapatumumab
and the design of additional clinical trials of mapatumumab
including studies in relapsed or refractory FL.
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Table 2 Number of patients with treatment–emergent AEs by severity
regardless of relationship to study drug (for X10% of subjects, n¼40)
Preferred term
Grade
1
Grade
2
Grade
3
Grade
4
Fatigue 12 (30.0%) 7 (17.5%) — —
Nausea 9 (22.5%) 4 (10.0%) 1 (2.5%) —
Diarrhoea 12 (30.0%) — — —
Pyrexia 8 (20.0%) 2 (5.0%) 1 (2.5%) —
Oedema peripheral 7 (17.5%) 3 (7.5%) — —
Anorexia 6 (15.0%) 2 (5.0%) — —
Constipation 5 (12.5%) 3 (7.5%) — —
Upper respiratory tract infection 4 (10.0%) 3 (7.5%) 1 (2.5%) —
Vomiting 4 (10.0%) 3 (7.5%) 1 (2.5%) —
Back pain 1 (2.5%) 4 (10.0%) 2 (5.0%) —
Cough 6 (15.0%) 1 (2.5%) — —
Abdominal pain 2 (5.0%) 1 (2.5%) 3 (7.5%) —
Dizziness 6 (15.0%) — — —
Dyspnoea 4 (10.0%) 1 (2.5%) — 1 (2.5%)
Chills 5 (12.5%) — — —
Dyspepsia 4 (10.0%) 1 (2.5%) — —
Headache 3 (7.5%) 1 (2.5%) 1 (2.5%) —
Lymph node pain 4 (10.0%) 1 (2.5%) — —
Pain in extremity 2 (5.0%) 2 (5.0%) 1 (2.5%) —
Pruritus 3 (7.5%) 2 (5.0%) — —
Weight decreased 4 (10.0%) 1 (2.5%) — —
Anaemia — 2 (5.0%) 2 (5.0%) —
Asthenia 4 (10.0%) — — —
Hyperglycaemia 1 (2.5%) 3 (7.5%) — —
Muscle spasms 3 (7.5%) 1 (2.5%) — —
Insomnia 4 (10%) — — —
Abbreviation: AEs¼adverse events.
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Figure 2 Plasma mapatumumab concentrations observed for individual
patients following 3 or 10mgkg
 1 mapatumumab i.v. infusion doses given
21 days apart, with the expected minimum to maximum concentration
range based on Phase 1 study results. (A) 3mgkg
 1 mapatumumab and
(B)1 0m gk g
 1 mapatumumab.
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